Overview

Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label trial of Gefitinib and docetaxel in patients having one prior regimen of chemotherapy for with metastatic pancreatic carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
AstraZeneca
Treatments:
Docetaxel
Gefitinib